 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- | Lasvic tablet (lascufloxacin oral) / Kyorin
Biomarker, Journal, Next-generation sequencing: Temporal effects of lascufloxacin on human gut and salivary microbiota: analysis using next-generation sequencing method. (Pubmed Central) - Jan 15, 2025
We elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days.
- | Lasvic tablet (lascufloxacin oral) / Kyorin, Lasvic Intravenous (lascufloxacin IV) / Kyorin
Journal: Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol. (Pubmed Central) - Feb 24, 2023
NHCAP is a common pneumonia in clinical settings and a notable pneumonia whose mortality is high compared to community-acquired pneumonia. The present study showed the efficacy and safety of LSFX against NHCAP, which could lead to a larger number of therapeutic options for NHCAP.
- || lascufloxacin oral (KRP-AM1977X) / Kyorin
Clinical, PK/PD data, Journal: Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men. (Pubmed Central) - Dec 18, 2020
After single-dose oral administration of LSFX 200 mg (capsules) to six elderly people in fasting state, its pharmacokinetic parameters were similar to those in non-elderly people, with no significant safety concerns. Therefore, adjustment of dosage and administration was considered to be unnecessary for LSFX administration to elderly individuals.
- | lascufloxacin oral (KRP-AM1977X) / Kyorin
Clinical, PK/PD data, Journal: Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers. (Pubmed Central) - Apr 21, 2019
Drug levels in epithelial lining fluid and alveolar macrophages exceeded the MIC90 values for common respiratory pathogens. (This study was registered at JAPIC under registration number JapicCTI- 142547.).